Free Trial

Grifols (GRFS) Stock Forecast & Price Target

Grifols logo
$9.44 -0.11 (-1.15%)
(As of 03:28 PM ET)

Grifols - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
1
Buy
1

Based on 3 Wall Street analysts who have issued ratings for Grifols in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 1 has given a sell rating, 1 has given a hold rating, and 1 has given a strong buy rating for GRFS.

Consensus Price Target

$10.50
11.23% Upside
According to the 3 analysts' twelve-month price targets for Grifols, the average price target is $10.50. The highest price target for GRFS is $10.50, while the lowest price target for GRFS is $10.50. The average price target represents a forecasted upside of 11.23% from the current price of $9.44.
Get the Latest News and Ratings for GRFS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Grifols and its competitors.

Sign Up

GRFS Analyst Ratings Over Time

TypeCurrent Forecast
11/16/23 to 11/15/24
1 Month Ago
10/17/23 to 10/16/24
3 Months Ago
8/18/23 to 8/17/24
1 Year Ago
11/16/22 to 11/16/23
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.50$10.50$10.50N/A
Forecasted Upside11.23% Upside23.67% Upside48.73% UpsideN/A
Consensus Rating
Hold
Reduce
Reduce
Hold

GRFS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GRFS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Grifols Stock vs. The Competition

TypeGrifolsMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside9.95% Upside26,221.89% Upside8.88% Upside
News Sentiment Rating
Neutral News

See Recent GRFS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/29/2024Berenberg Bank
2 of 5 stars
T. Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/12/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 DowngradeHold ➝ Sell
12/5/2023JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetNeutral ➝ Neutral$10.00 ➝ $10.50+6.82%
8/29/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
2/16/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight
2/6/2023AlphaValue
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeBuy
1/18/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
11/25/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:45 PM ET.


GRFS Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Grifols is $10.50, with a high forecast of $10.50 and a low forecast of $10.50.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last twelve months. There is currently 1 sell rating, 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" GRFS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRFS, but not buy additional shares or sell existing shares.

According to analysts, Grifols's stock has a predicted upside of 11.23% based on their 12-month stock forecasts.

Over the previous 90 days, Grifols's stock had 1 upgrade by analysts.

Grifols has been rated by research analysts at Berenberg Bank in the past 90 days.

Analysts like Grifols less than other "medical" companies. The consensus rating for Grifols is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GRFS compares to other companies.


This page (NASDAQ:GRFS) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners